FDA Approved Leukemia Drug Shows Promising Activity In Ovarian Cancer Cells

Wed, 11 Nov 2009 01:00:00 PST
http://www.medicalnewstoday.com/articles/170504.php

The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.

Nektar Completes Enrollment Ahead Of Schedule In Phase 2 Clinical Trial Evaluating NKTR-102 In Patients With Platinum-Resistant Ovarian Cancer

Thu, 29 Oct 2009 02:00:00 PST
http://www.medicalnewstoday.com/articles/169087.php

Nektar Therapeutics (Nasdaq: NKTR) announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.

Endocyte Presents Data On EC145 In Treatment Of Ovarian Cancer Before The European Society Of Gynaecologic Oncology

Thu, 22 Oct 2009 21:00:00 PST
http://www.medicalnewstoday.com/articles/168365.php

Officials of Endocyte Inc., a cancer drug discovery and development company, presented data from a Phase 2a clinical trial for EC145, currently in development as a potential treatment for advanced ovarian cancer. Results were presented at the European Society of Gynaecologic Oncology meeting in Belgrade, Serbia. In 49 women with advanced-stage ovarian cancer, EC145 was shown to have anti-tumor activity in a significant percentage of trial participants.

News From The American Journal Of Pathology, November 2009

Wed, 21 Oct 2009 03:00:00 PST
http://www.medicalnewstoday.com/articles/168103.php

A group led by Dr. Dieter Brömme at the University of British Columbia has demonstrated that glycosaminoglycans (GAGs) contribute to skeletal abnormalities in patients with lysosomal storage diseases. Their report can be found in the November 2009 issue of The American Journal of Pathology. Mucopolysaccharidoses (MPS) are a group of diseases in which the dysfunction of a lysosomal enzyme results in decreased breakdown of GAGs, a type of carbohydrate, in various tissues.

Metals Could Forge New Cancer Drug

Mon, 19 Oct 2009 04:00:00 PST
http://www.medicalnewstoday.com/articles/167836.php

Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds.

CALYPSO Trial Shows New Chemotherapy Combination Prolongs Progression Free Survival In Ovarian Cancer

Sun, 18 Oct 2009 00:00:00 PST
http://www.medicalnewstoday.com/articles/167718.php

Treating women with relapsed platinum-sensitive ovarian cancer with combined carboplatin and pegylated liposomal doxorubicin prolongs progression free survival and is associated with a lower risk of severe, long lasting nerve damage than standard carboplatin/paclitaxel treatment.

Ovarian Cancer Patients Have Lower Death Risk When Treated By Experts

Sun, 18 Oct 2009 00:00:00 PST
http://www.medicalnewstoday.com/articles/167720.php

Women with ovarian cancer are less likely to die from their disease if they are treated by specialist gynaecological oncologists than if they are cared for by general gynaecologists, according to the results of a study carried out in Scotland, UK, and reported at this week's 16th International Meeting of the European Society of Gynaecological Oncology (ESGO) in Belgrade, Serbia.

European Patent Office To Issue Patent To Phyton Biotech Covering Methods Of Making Taxanes - Compounds Useful In Cancer Treatment

Tue, 13 Oct 2009 20:00:00 PST
http://www.medicalnewstoday.com/articles/167200.php

Phyton Biotech GmbH, a world leader in plant cell culture technology, reports that the European Patent Office has announced its intention to grant a European patent to Phyton covering methods of producing taxanes such as paclitaxel. Paclitaxel, the active ingredient in Bristol-Myers Squibb's TAXOL®, is useful in the treatment of breast, ovarian, lung, and other forms of cancer.

Farletuzumab Data Presented On Phase II Clinical Trial In First-Relapsed Ovarian Cancer Subjects

Fri, 25 Sep 2009 02:00:00 PST
http://www.medicalnewstoday.com/articles/165172.php

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA).

Gene Variant Shows Strong Gender Bias For Cancer Predisposition

Wed, 23 Sep 2009 06:00:00 PST
http://www.medicalnewstoday.com/articles/164929.php

Cancer predisposition resulting from the presence of a specific gene variant shows a strong gender bias, researchers at the University of Cincinnati (UC) have demonstrated. In addition, the research indicates that the risk for development of cancer in individuals harboring the gene variant can be further increased as a result of environmental exposure.

Dose-Dense Chemotherapy Improves Both Overall And Progression-Free Survival In Advanced Ovarian Cancer

Tue, 22 Sep 2009 00:00:00 PST
http://www.medicalnewstoday.com/articles/164638.php

Women given a more intensive 'dose-dense' regimen of chemotherapy survive longer and have a higher-rate of progression free survival, concludes an Article published Online First in an upcoming edition of The Lancet. The Article is written by Dr Noriyuki Katsumata, National Cancer Center Hospital, Tokyo, Japan, and colleagues. Paclitaxel and carboplatin given every 3 weeks is currently considered standard first-line chemotherapy for advanced epithelial ovarian cancer.

Clarifying Myths: Ovarian Cancer Can Have Early Symptoms, Can Be Successfully Treated

Thu, 17 Sep 2009 02:00:00 PST
http://www.medicalnewstoday.com/articles/164215.php

Ovarian cancer is a frightening diagnosis that often comes after the cancer has spread. As a result, it's the most deadly of the gynecological cancers. But not all the news about ovarian cancer is grim. Incidence is declining. Doctors are learning more about early symptoms and more effective treatments. The September issue of Mayo Clinic Women's HealthSource looks at myths and facts about ovarian cancer. Myth: There are no early symptoms.

New Drug That Targets Inherited Breast And Ovarian Cancers May Work Against Other Cancers, Study

Wed, 16 Sep 2009 11:00:00 PST
http://www.medicalnewstoday.com/articles/164196.php

A new study suggests that a new type of cancer drug called PARP inhibitors, including a new drug called olaparib that is currently showing promising results in trials as a targeted treatment for inherited forms of breast and ovarian cancer, may also be effective against other cancers.

New Research May Aid Earlier Detection Of Ovarian Cancer

Wed, 16 Sep 2009 02:00:00 PST
http://www.medicalnewstoday.com/articles/164062.php

Two recent studies may provide improved insight into detecting ovarian cancer, one of the most deadly forms of the disease because it is difficult to catch in its earliest, most curable stages, the Wall Street Journal reports. In a

U.S. Food And Drug Administration Clears Vermillion's OVA1(TM) Test To Determine Likelihood Of Ovarian Cancer In Women With Pelvic Mass

Sat, 12 Sep 2009 01:00:00 PST
http://www.medicalnewstoday.com/articles/163761.php

The U.S. Food and Drug Administration (FDA) cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass. OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiological test results fail to indicate malignancy. The test was developed by Vermillion, Inc. (OTC: VRMLQ.

FDA Clears A Test For Ovarian Cancer

Sat, 12 Sep 2009 01:00:00 PST
http://www.medicalnewstoday.com/articles/163762.php

The U.S. Food and Drug Administration cleared a test that can help detect ovarian cancer in a pelvic mass that is already known to require surgery. The test, called OVA1, helps patients and health care professionals decide what type of surgery should be done and by whom. OVA1 identifies some women who will benefit from referral to a gynecological oncologist for their surgery, despite negative results from other clinical and radiographic tests for ovarian cancer.

FDA Issues Complete Response Letter For Trabectedin Combined With DOXIL

Fri, 11 Sep 2009 02:00:00 PST
http://www.medicalnewstoday.com/articles/163619.php

Centocor Ortho Biotech Products, L.P. announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for trabectedin when administered in combination with DOXIL(R) (doxorubicin HCI liposome injection) for the treatment of women with relapsed ovarian cancer.

NCI Renews Fox Chase / Penn Ovarian Cancer "SPORE" Grant For A Third Five-Year Term

Sat, 05 Sep 2009 00:00:00 PST
http://www.medicalnewstoday.com/articles/163029.php

National Cancer Institute (NCI) has renewed a $11.5 million Specialized Program of Research Excellence (SPORE) grant in prevention, diagnosis and treatment of ovarian cancer, which supports multidisciplinary research at Fox Chase Cancer Center and the University of Pennsylvania. First approved in 1999, this marks the third five-year term for the Fox Chase-Penn Ovarian SPORE.

OSI Pharmaceuticals Initiates Phase III Registration-Oriented Study For OSI-906 In Adrenocortical Carcinoma And Phase I/II Study In Ovarian Cancer

Fri, 04 Sep 2009 05:00:00 PST
http://www.medicalnewstoday.com/articles/163036.php

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today the initiation of two clinical trials with OSI-906, the Company's potential first-in-class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).

Loehmann's To Host Fashion Funds Hope In-Store Event On September 24th To Benefit Ovarian Cancer Research Fund (OCRF)

Wed, 02 Sep 2009 07:00:00 PST
http://www.medicalnewstoday.com/articles/162717.php

September is Ovarian Cancer Awareness Month. On Thursday, September 24th, fashion-savvy, budget-minded shoppers can support cancer research while receiving special savings on leading designer apparel for one day only, at any of the more than sixty Loehmann's stores across the country.

Ovarian Cancer Risk: Scientists From University Of Hawaii At Manoa Find Genetic Marker

Wed, 02 Sep 2009 01:00:00 PST
http://www.medicalnewstoday.com/articles/162567.php

A new genetic marker associated with ovarian cancer risk was recently discovered by an international research group, led by scientists from the Cancer Research Genetic Epidemiology Unit in the United Kingdom. Drs.

Potential New Treatment For Ovarian Cancer

Tue, 01 Sep 2009 06:00:00 PST
http://www.medicalnewstoday.com/articles/162510.php

In the future, women with metastatic ovarian cancer could be treated with a radioactive substance that can seek and destroy tumour cells. An initial study in patients conducted jointly by the Sahlgrenska Academy at the University of Gothenburg and Sahlgrenska University Hospital has found that the treatment has no unwanted side-effects.

Major Grant For Ovarian Cancer Research Awarded To Mayo Clinic

Sat, 29 Aug 2009 00:00:00 PST
http://www.medicalnewstoday.com/articles/162177.php

Investigators at the Mayo Clinic Cancer Center have received a five-year, $11.5 million grant to translate research into treatments for women with ovarian cancer. Every year in the United States, more than 16,000 women die from the disease and another 22,000 are diagnosed, according to the National Cancer Institute (NCI). The award from the NCI is called a Specialized Program of Research Excellence (SPORE) grant.

More Than Half Of Women With Ovarian Cancer Face Delay In Diagnosis

Wed, 26 Aug 2009 11:00:00 PST
http://www.medicalnewstoday.com/articles/161930.php

Many women with ovarian cancer can go undiagnosed for months because their symptoms are not always being investigated promptly, warn researchers in a study published on bmj.com today. The study identifies three key symptoms associated with ovarian cancer that should help clinicians decide whether to investigate further. Yet one of these symptoms is not included in current guidance for urgent investigation.

Ovarian Cancer Rates Fall 20 Per Cent

Wed, 26 Aug 2009 03:00:00 PST
http://www.medicalnewstoday.com/articles/161873.php

Ovarian cancer rates have fallen by almost 20 per cent in a decade, according to Cancer Research UK today (Wednesday). Rates for women in their 50s and early 60s are nearly 20 per cent lower than they were in 1998. And for women under 50* rates are 14 per cent lower than they were at their peak in 1997.